Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults

Toxicology and Applied Pharmacology

Volumn 224, Issue 2, 2007, Pages 202-206

  Petersen, Maria Skaalum ^a   Halling, Jónrit ^a   Damkier, Per ^a,b   Nielsen, Flemming ^a   Grandjean, Philippe ^a,d   Weihe, Pál ^a,c   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

6 Hydroxycortisol cortisol ratio; CYP3A4; Faroe Islands; Persistent organohalogen pollutants; Polychlorinated biphenyls

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 6BETA HYDROXYHYDROCORTISONE; CELL NUCLEUS RECEPTOR; CHLORPHENOTANE; CYTOCHROME P450 3A4; HYDROCORTISONE; LIPID; ORGANOHALOGEN DERIVATIVE; POLYCHLORINATED BIPHENYL; PREGNANE X RECEPTOR;

ADULT; ARTICLE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PHENOTYPE; POLLUTANT; RECEPTOR UPREGULATION;

ADOLESCENT; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DDT; DICHLORODIPHENYL DICHLOROETHYLENE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; ENZYME INDUCTION; FEMALE; GENETICS, POPULATION; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; POLYCHLORINATED BIPHENYLS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEX FACTORS; TOXICOGENETICS;

EID: 34848830702     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.07.002     Document Type: Article

References (39)

1. Ahlborg U.G., Becking G.C., Birnbaum L.S., Brouwer A., Derks H.J.G.M., Feeley M., Golor G., Hanberg A., Larsen J.C., Liem A.K.D., Safe S.H., Schlatter C., Waern F., Younes M., and Yrjanheikki E. Toxic equivalency factors for dioxin-like PCBs. Chemosphere 28 (1994) 1049-1067
2. Bienvenu T., Rey E., Pons G., d'Athis P., and Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 29 (1991) 441-445
3. Bloch D., Desportes G., Hoydal K., and Jean P. Pilot whaling in the Faroe Islands, July 1986-July 1988. North Atl. Stud. 2 (1990) 36-44
4. Damkier P., and Brosen K. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin. Pharmacol. Ther. 68 (2000) 199-209
5. In: Deutch B., and Hansen J.C. (Eds). AMAP Greenland and the Faroe Islands 1997-2001 (2003), Danish Environmental Protection Agency, Copenhagen
6. El Desoky E.S., Mohamed H.O., Farghaly W.M., Hamed S.A., Hedaya M.A., and Siest J.P. Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. Pharmacol. Res. 51 (2005) 575-580
7. Galteau M.M., and Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 59 (2003) 713-733
8. Gibson G.G., Plant N.J., Swales K.E., Ayrton A., and El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32 (2002) 165-206
9. Grandjean P., Weihe P., Needham L.L., Burse V.W., Patterson Jr. D.G., Sampson E.J., Jørgensen P.J., and Vahter M. Effect of a seafood diet on mercury, selenium, arsenic, and PCBs and other organochlorines in human milk. Environ. Res. 71 (1995) 29-38
10. Grandjean P., Weihe P., Burse V.W., Needham L.L., Storr-Hansen E., Heinzow B., Debes F., Murata K., Simonsen H., Ellefsen P., Budtz-Jorgensen E., Keiding N., and White R.F. Neurobehavioral deficits associated with PCB in 7-year-old children prenatally exposed to seafood neurotoxicants. Neurotoxicol. Teratol. 23 (2001) 305-317
11. Guengerich F.P., and Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4 (1991) 391-407
12. Halling J., Petersen M.S., Damkier P., Nielsen F., Grandjean P., Weihe P., Lundgren S., Lundblad M.S., and Brosen K. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol. 61 (2005) 491-497
13. Harmsen S., Meijerman I., Beijnen J.H., and Schellens J.H. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev. 33 (2007) 369-380
14. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50 (1995) 222-239
15. Hjalgrim H., Tulinius H., Dalberg J., Hardarson S., Frisch M., and Melbye M. High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. Br. J. Cancer 77 (1998) 1190-1193
16. Hunt C.M., Westerkam W.R., and Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44 (1992) 275-283
17. Inagaki K., Inagaki M., Kataoka T., Sekido I., Gill M.A., and Nishida M. A wide inter-individual variability of urinary 6β-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther. Drug Monit. 24 (2002) 722-727
18. Lake B.G., Charzat C., Tredger J.M., Renwick A.B., Beamand J.A., and Price R.J. Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 26 (1996) 297-306
19. Longnecker M.P., Wolff M.S., Gladen B.C., Brock J.W., Grandjean P., Jacobson J.L., Korrick S.A., Rogan W.J., Weisglas-Kuperus N., Hertz-Picciotto I., Ayotte P., Stewart P., Winneke G., Charles M.J., Jacobson S.W., Dewailly E., Boersma E.R., Altshul L.M., Heinzow B., Pagano J.J., and Jensen A.A. Comparison of polychlorinated biphenyl (PCB) levels across studies of human neurodevelopment. Environ. Health Perspect. 11 (2003) 165-170
20. Lykkesfeldt J., Loft S., and Poulsen H. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J. Chromatogr. B, Biomed. Appl. 660 (1994) 23-29
21. Medina-Diaz I.M., Arteaga-Illan G., de Leon M.B., Cisneros B., Sierra-Santoyo A., Vega L., Gonzalez F.J., and Elizondo G. Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p′-1,1,1,-trichloro-2,2-bis(p-chlorophenyl)ethane. Drug Metab. Dispos. 35 (2007) 95-102
22. Milman N., Steig T., Koefoed P., Pedersen P., Fenger K., and Nielsen F.C. Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Ann. Hematol. 84 (2004) 146-149
23. Nakamura J., and Yakata M. Age- and sex-related differences in urinary excretion of 6 beta-hydroxycortisol in humans. Clin. Chim. Acta 152 (1985) 193-197
24. Nebert D.W., and Dalton T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev., Cancer 6 (2006) 947-960
25. Okey A.B. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45 (1990) 241-298
26. Park B.K. Assessment of urinary 6β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br. J. Clin. Pharmacol. 12 (1981) 97-102
27. Petersen M.S., Halling J., Damkier P., Nielsen F., Grandjean P., Weihe P., and Brosen K. Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. Eur. J. Clin. Pharmacol. 62 (2006) 1041-1048
28. Safe S. Polychlorinated biphenyles (PCBs): environmental Impact, biochemical and toxic responses and implication for risk assessment. Crit. Rev. Toxicol. 24 (1994) 87-149
29. Santer R., Kinner M., Steuerwald U., Kjaergaard S., Skovby F., Simonsen H., Shaiu W.-L., Chen T.-T., Schneppenheim R., and Schaub J. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. Eur. J. Hum. Gen. 9 (2001) 388-391
30. Schwartz M., Sorensen N., Brandt N.J., Hogdall E., and Holm T. High incidence of cystic fibrosis on the Faroe Islands: a molecular and genealogical study. Hum. Genet. 95 (1995) 703-706
31. Shimada T., Iwasaki M., Martin M.V., and Guengerich F.P. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res. 49 (1989) 3218-3228
32. Shimida T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
33. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
34. Thummel K.E., and Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 389-430
35. Watkins P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4 (1994) 171-184
36. Waxman D.J., Attisano C., Guengerich F.P., and Lapenson D.P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263 (1988) 424-436
37. Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm. 24 (1996) 475-490
38. Zhou S., Chan E., Lim L.Y., Boelsterli U.A., Li S.C., Wang J., Zhang Q., Huang M., and Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 5 (2004) 415-442
39. Zhu B., Liu Z.Q., Chen G.L., Chen X.P., Ou-Yang D.S., Wang L.S., Huang S.L., Tan Z.R., and Zhou H.H. The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. 55 (2003) 264-269